Kawasaki disease following immunization reported to the Canadian Immunization Monitoring Program ACTive (IMPACT) from 2013 to 2018
Kawasaki disease (KD) is an acute systemic vasculitis primarily affecting children younger than 5 y of age that has been reported as an adverse event following immunization (AEFI). The Canadian Immunization Monitoring Program ACTive (IMPACT) conducts active surveillance for KD following immunization...
| Main Authors: | , , , , , , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Taylor & Francis Group
2022-11-01
|
| Series: | Human Vaccines & Immunotherapeutics |
| Subjects: | |
| Online Access: | http://dx.doi.org/10.1080/21645515.2022.2088215 |
| _version_ | 1797673176789942272 |
|---|---|
| author | Khaled Alsager Nirma Khatri Vadlamudi Taj Jadavji Julie A. Bettinger Cora Constantinescu Wendry Vaudry Ben Tan Laura Sauvé Manish Sadarangani Scott A. Halperin Karina A. Top for the IMPACT Investigators |
| author_facet | Khaled Alsager Nirma Khatri Vadlamudi Taj Jadavji Julie A. Bettinger Cora Constantinescu Wendry Vaudry Ben Tan Laura Sauvé Manish Sadarangani Scott A. Halperin Karina A. Top for the IMPACT Investigators |
| author_sort | Khaled Alsager |
| collection | DOAJ |
| description | Kawasaki disease (KD) is an acute systemic vasculitis primarily affecting children younger than 5 y of age that has been reported as an adverse event following immunization (AEFI). The Canadian Immunization Monitoring Program ACTive (IMPACT) conducts active surveillance for KD following immunization across Canada. We characterized KD cases reported to IMPACT between 2013 and 2018. Cases admitted to an IMPACT hospital with a physician diagnosis of complete or incomplete KD with onset 0–42 d following vaccination were reviewed. Cases meeting the Brighton Collaboration case definition (BCCD) levels of diagnostic certainty levels 1 a/b, 2a/b or 3a-e were defined as KD cases. Demographic and vaccination characteristics were compared between KD cases and non-cases. Of 84 cases reviewed, 58 met the BCCD: 47 (81%) cases met level 1a (Complete KD), 8 (14%) met level 1b (Incomplete KD), 2 (3%) met level 2a, and 1 (2%) met level 2c (Probable KD). Median age at admission was 13 months (interquartile range 7–26 months). A median of 9.5 cases were reported per year (range 4–14). Thirty-one (53%) KD cases were temporally associated with diphtheria-tetanus acellular pertussis containing vaccinations, followed by 21 (36%) cases with pneumococcal conjugate vaccines. Symptom onset was 0–14 d after vaccination in 32 (55%) cases. Echocardiogram results were available for 43 (74%) cases with 22 reported as abnormal. Age, sex, interval to symptom onset, and vaccines received were similar between KD cases and non-cases. No safety signals were detected in these data. |
| first_indexed | 2024-03-11T21:41:12Z |
| format | Article |
| id | doaj.art-ebaade109a064b04be023eb1c768e76c |
| institution | Directory Open Access Journal |
| issn | 2164-5515 2164-554X |
| language | English |
| last_indexed | 2024-03-11T21:41:12Z |
| publishDate | 2022-11-01 |
| publisher | Taylor & Francis Group |
| record_format | Article |
| series | Human Vaccines & Immunotherapeutics |
| spelling | doaj.art-ebaade109a064b04be023eb1c768e76c2023-09-26T13:19:07ZengTaylor & Francis GroupHuman Vaccines & Immunotherapeutics2164-55152164-554X2022-11-0118510.1080/21645515.2022.20882152088215Kawasaki disease following immunization reported to the Canadian Immunization Monitoring Program ACTive (IMPACT) from 2013 to 2018Khaled Alsager0Nirma Khatri Vadlamudi1Taj Jadavji2Julie A. Bettinger3Cora Constantinescu4Wendry Vaudry5Ben Tan6Laura Sauvé7Manish Sadarangani8Scott A. Halperin9Karina A. Top10for the IMPACT InvestigatorsAlberta Children’s HospitalBC Children’s Hospital Research InstituteAlberta Children’s HospitalBC Children’s Hospital Research InstituteAlberta Children’s HospitalUniversity of AlbertaJim Pattison Children’s HospitalBC Children’s Hospital Research InstituteBC Children’s Hospital Research InstituteDalhousie University, and Canadian Center for Vaccinology, IWK HealthDalhousie University, and Canadian Center for Vaccinology, IWK HealthKawasaki disease (KD) is an acute systemic vasculitis primarily affecting children younger than 5 y of age that has been reported as an adverse event following immunization (AEFI). The Canadian Immunization Monitoring Program ACTive (IMPACT) conducts active surveillance for KD following immunization across Canada. We characterized KD cases reported to IMPACT between 2013 and 2018. Cases admitted to an IMPACT hospital with a physician diagnosis of complete or incomplete KD with onset 0–42 d following vaccination were reviewed. Cases meeting the Brighton Collaboration case definition (BCCD) levels of diagnostic certainty levels 1 a/b, 2a/b or 3a-e were defined as KD cases. Demographic and vaccination characteristics were compared between KD cases and non-cases. Of 84 cases reviewed, 58 met the BCCD: 47 (81%) cases met level 1a (Complete KD), 8 (14%) met level 1b (Incomplete KD), 2 (3%) met level 2a, and 1 (2%) met level 2c (Probable KD). Median age at admission was 13 months (interquartile range 7–26 months). A median of 9.5 cases were reported per year (range 4–14). Thirty-one (53%) KD cases were temporally associated with diphtheria-tetanus acellular pertussis containing vaccinations, followed by 21 (36%) cases with pneumococcal conjugate vaccines. Symptom onset was 0–14 d after vaccination in 32 (55%) cases. Echocardiogram results were available for 43 (74%) cases with 22 reported as abnormal. Age, sex, interval to symptom onset, and vaccines received were similar between KD cases and non-cases. No safety signals were detected in these data.http://dx.doi.org/10.1080/21645515.2022.2088215adverse eventsimmunizationpediatricsvasculitisvaccinationvaccine safety |
| spellingShingle | Khaled Alsager Nirma Khatri Vadlamudi Taj Jadavji Julie A. Bettinger Cora Constantinescu Wendry Vaudry Ben Tan Laura Sauvé Manish Sadarangani Scott A. Halperin Karina A. Top for the IMPACT Investigators Kawasaki disease following immunization reported to the Canadian Immunization Monitoring Program ACTive (IMPACT) from 2013 to 2018 Human Vaccines & Immunotherapeutics adverse events immunization pediatrics vasculitis vaccination vaccine safety |
| title | Kawasaki disease following immunization reported to the Canadian Immunization Monitoring Program ACTive (IMPACT) from 2013 to 2018 |
| title_full | Kawasaki disease following immunization reported to the Canadian Immunization Monitoring Program ACTive (IMPACT) from 2013 to 2018 |
| title_fullStr | Kawasaki disease following immunization reported to the Canadian Immunization Monitoring Program ACTive (IMPACT) from 2013 to 2018 |
| title_full_unstemmed | Kawasaki disease following immunization reported to the Canadian Immunization Monitoring Program ACTive (IMPACT) from 2013 to 2018 |
| title_short | Kawasaki disease following immunization reported to the Canadian Immunization Monitoring Program ACTive (IMPACT) from 2013 to 2018 |
| title_sort | kawasaki disease following immunization reported to the canadian immunization monitoring program active impact from 2013 to 2018 |
| topic | adverse events immunization pediatrics vasculitis vaccination vaccine safety |
| url | http://dx.doi.org/10.1080/21645515.2022.2088215 |
| work_keys_str_mv | AT khaledalsager kawasakidiseasefollowingimmunizationreportedtothecanadianimmunizationmonitoringprogramactiveimpactfrom2013to2018 AT nirmakhatrivadlamudi kawasakidiseasefollowingimmunizationreportedtothecanadianimmunizationmonitoringprogramactiveimpactfrom2013to2018 AT tajjadavji kawasakidiseasefollowingimmunizationreportedtothecanadianimmunizationmonitoringprogramactiveimpactfrom2013to2018 AT julieabettinger kawasakidiseasefollowingimmunizationreportedtothecanadianimmunizationmonitoringprogramactiveimpactfrom2013to2018 AT coraconstantinescu kawasakidiseasefollowingimmunizationreportedtothecanadianimmunizationmonitoringprogramactiveimpactfrom2013to2018 AT wendryvaudry kawasakidiseasefollowingimmunizationreportedtothecanadianimmunizationmonitoringprogramactiveimpactfrom2013to2018 AT bentan kawasakidiseasefollowingimmunizationreportedtothecanadianimmunizationmonitoringprogramactiveimpactfrom2013to2018 AT laurasauve kawasakidiseasefollowingimmunizationreportedtothecanadianimmunizationmonitoringprogramactiveimpactfrom2013to2018 AT manishsadarangani kawasakidiseasefollowingimmunizationreportedtothecanadianimmunizationmonitoringprogramactiveimpactfrom2013to2018 AT scottahalperin kawasakidiseasefollowingimmunizationreportedtothecanadianimmunizationmonitoringprogramactiveimpactfrom2013to2018 AT karinaatop kawasakidiseasefollowingimmunizationreportedtothecanadianimmunizationmonitoringprogramactiveimpactfrom2013to2018 AT fortheimpactinvestigators kawasakidiseasefollowingimmunizationreportedtothecanadianimmunizationmonitoringprogramactiveimpactfrom2013to2018 |